The EASD/European Society of Cardiology (ESC) guidelines recommend pharmacotherapy focusing on agents with proven cardiovascular benefits like SGLT2 inhibitors for patients with T2DM and established cardiovascular disease. Here, SLC5A2 is linked to type 2 diabetes mellitus.